Health News
Cirrhosis Survival Spiked
Good news for cirrhosis patients: Survival may be much more common than it once was.
FDA Approves TOBI Podhaler
The US Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.